Name: China Ibrutinib Powder Suppliers, Manufacturers, Factory - Wholesale Price - Sonwu
Brand: Sonwu
SKU: 164176865

Xi'an Sonwu Biotech Co., Ltd. is one of the most professional manufacturers and suppliers of ibrutinib powder in China. We warmly welcome yuo to wholesale bulk ibrutinib powder for sale here from our factory. Quality products and reasonable price are available.

What Is Ibrutinib

Ibrutinib powder is a Bruton's tyrosine kinase (BTK) inhibitor used in treating CLL and MCL. Both MCL and CLL belong to B-cell non-Hodgkin's lymphoma, characterized by refractory and easy recurrence. Commonly used chemoimmunotherapy is not targeted; grade 3 or 4 adverse effects are common. Ibrutinib can target and bind to BTK necessary for the formation, differentiation, information transmission, and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of necrotic cells; it can be absorbed rapidly after oral administration, within 1 to 2 hours Reaching the maximum blood concentration, the adverse reaction is grade 1 or 2. It will become a new option for the treatment of CLL and MCL. Ibrutinib is an oral first-in-class Bruton's tyrosine kinase (BTK) inhibitor drug. Approved for the treatment of MCL and CLL on February 12, 2014. The drug irreversibly inhibits BTK by selectively covalently binding to the cysteine residue (Cys-481) in the active site of the target protein Btk, thereby effectively preventing the migration of necrotic cells from B cells to cells suitable for the growth environment.Xi'an Sonwnu can provide Ibrutinib supplements, and the stock is currently sufficient. If you are interested, you can contact Xi'an Sonwnu at any time.

Ibrutinib

COA

COA of Ibrutinib poeder

Where to Buy Ibrutinib

Xi'an Sonwu Biotech Co. ltd, the products produced are strictly controlled in quality and have been rigorously screened from the beginning of the raw materials. In the product production process, we handle every detail well, minimize costs, and enable our customers to get cost-effective products. Many customers have given good feedback to our products after receiving the goods.

To ensure the quality of the products, we can provide samples for testing. Here is the quantity.

Form	Sample	MOQ
Powder	10g	100g

Customers’s Good Comment

Sonwu (6)

How Does Ibrutinib Work

The B-cell antigen receptor (BCR) signaling pathway is a crucial driver of the growth and dissemination of many serious diseases. As an integral participant of the BCR signaling peptide, BTK is essential for forming, differentiation, information transmission, and survival of B lymphocytes. BTK is a signal peptide molecule that BCR channels can recognize. When the signal peptide molecule passes through the B lymphocyte surface receptor, the necessary channels for B lymphocytes to achieve translocation, chemotaxis, and adhesion are activated, which provides for the formation of B cells.

Ibrutinib powder is a small molecule BTK inhibitor that can selectively covalently bind to the cysteine residue (Cys-481) on the active site of BTK, irreversibly inhibit the activity of BTK, and then inhibit BCR The activation of signaling pathways can effectively prevent bad cells from migrating from B cells to lymphoid tissues suitable for growth, reduce the malignant proliferation of B cells and induce cell apoptosis, thereby playing a role in the treatment of CLL and MCL. Nonclinical studies have shown that ibrutinib can inhibit the proliferation and survival of malignant B lymphocytes in vivo.

Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Chronic lymphocytic leukemia (CLL) is a chronic hematologic malignancy caused by the clonal proliferation of morphologically mature lymphocytes instead of normal apoptosis in lymphoid tissues. CLL has specific family heredity and belongs to B cell Non-Hodgkin'slymphoma, a more common type of NHL. Mantle cell lymphoma, MCL, is a rare B-cell NHL, accounting for about 5% to 10% of all NHL, and has the refractory and aggressive nature of malignant lymphoma. MCL is not easy to diagnose, and about 85% of patients are in stage III-IV at the time of diagnosis; it is easy to relapse, and it is the subtype of lymphoma with the lowest long-term survival rate in the Chemical book. Clinically, it often manifests as high fever and fatigue, enlarged spleen and lymph nodes, involvement of the gastrointestinal tract, and infiltration of the nervous system. The current first-line treatment for CLL is the FCR regimen, which is a combination of fludarabine (F), cyclophosphamide (C), and rituximab (R), which has a specific effect but no disease. The progression survival rate was 38%, and grade 3 or 4 adverse reactions occurred occasionally.

MCL often chooses anthracyclines or drugs containing high-dose cytarabine, but most are insensitive to conventional chemotherapy drugs. Although many medications have been used for treatment, the overall survival of patients has not been significantly prolonged[5]; Although drugs and monoclonal antibodies combined with chemotherapy are also used to treat MCL, the toxicity is high, the incidence of infection is about 14%, and the incidence of grade 3-4 adverse reactions is as high as 87%. Therefore, feasible treatment options and highly effective and safe drugs are yet to be launched.

Synthesis Method

Using 4-phenoxybenzoic acid (1) as raw material, chlorination, condensation with malononitrile, methylation, and cyclization with hydrazine hydrate were used to obtain intermediate 5. Compound 6 was synthesized from 5 and formamide ring Chemicalbook, and six was subjected to Mitsunobu reaction and removal of the Boc protecting group to obtain middle 8, which was reacted with acryloyl chloride to obtain ibrutinib.

Ibrutinib1

Side Effects

1. Common side effects:

● In adults: Diarrhea, tiredness, muscle and bone pain, rash, bruising

● In adults or children one year and older with cGVHD: Tiredness, muscle, and joint pain, nausea, low red blood cell count (anemia), fever, stomach pain, bruising, muscle cramps, pneumonia, diarrhea, mouth sores, headache.

2. Serious side effects:

● Bleeding that is abnormal and heavy

● Blood in the stool or black stool

● Pink or brown urine

● Prolonged headache

● Infection: Fever, chills, weakness, confusion, etc.

● Heart problems: ventricular arrhythmias, atrial fibrillation and flutter, heart failure, and death

● Hypertension

If you experience the above side effects after taking this product, don't hesitate to contact your doctor. Pay special attention to telling your doctor if you take other medicines before taking them. In addition, take it according to the doctor's recommended dosage.

What Is the Dosage of Ibrutinib

The recommended dose of Ibrutinib is for the following:

MCL: 560 mg once a day

CLL: 420 mg once a day

Patients 12 years and older: 420 mg once a day.

For patients aged 1 to less than 12 years: The recommended dose is 240 mg/m2 orally once daily (maximum dose 420 mg).

Factory Environment

1.Xi'an Sonwu Biotech Co.,Ltd has its own factory,so it has adequate stock. Also,Xi'an Sonwu has clean and tidy producing department with advanced equipment. With the lead of Xi'an Sonwu, researchers are constantly developing new products to meet customer's need.

2.Xi'an Sonwu Biotech Co.,Ltd has advanced test equipment and professional testers, which all show that Xi'an Sonwu aims to supply accurate and effective data and good service.

sonwu

Certificates

Sonwu (9)

Packing

Sonwu (10)

Recent Logistics

Sonwu (8)

Except guarantee the product’s, the other most important thing is customers could receive the goods smoothly. So, Xi’an Sonwu supplies all kinds of courier according to different need.

sonwu (11)